Patents by Inventor Khaled Yamout
Khaled Yamout has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11786536Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: GrantFiled: May 27, 2021Date of Patent: October 17, 2023Assignee: ESSENTIALIS, INC.Inventors: Neil M. Cowen, Khaled A. Yamout
-
Publication number: 20220233501Abstract: Methods of treatment include administering effective amounts of a nitrogen oxide (NO) donor (such as nicorandil) and a hydrogen sulfide (H2S) releasing agent (such as zofenopril) to a subject in need thereof. In various embodiments, the H2S releasing agent is administered in an amount that is effective to enhance the therapeutic efficacy of the NO donor. Coformulations of the H2S releasing agent and the NO donor are provided that are suitable for treating a number of conditions. In various embodiments, treatments for conditions such as chronic kidney disease, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, familial dilated cardiomyopathy and/or idiopathic dilated cardiomyopathy are provided.Type: ApplicationFiled: March 1, 2022Publication date: July 28, 2022Inventors: Neil M. Cowen, Khaled Yamout
-
Publication number: 20220047605Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: ApplicationFiled: May 27, 2021Publication date: February 17, 2022Inventors: Neil M. COWEN, Khaled A. YAMOUT
-
Patent number: 11045478Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: GrantFiled: November 11, 2019Date of Patent: June 29, 2021Assignee: ESSENTIALIS, INC.Inventors: Neil M. Cowen, Khaled A. Yamout
-
Publication number: 20200253926Abstract: Methods of treatment include administering effective amounts of a nitrogen oxide (NO) donor (such as nicorandil) and a hydrogen sulfide (H2S) releasing agent (such as zofenopril) to a subject in need thereof. In various embodiments, the H2S releasing agent is administered in an amount that is effective to enhance the therapeutic efficacy of the NO donor. Coformulations of the H2S releasing agent and the NO donor are provided that are suitable for treating a number of conditions. In various embodiments, treatments for conditions such as chronic kidney disease, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, familial dilated cardiomyopathy and/or idiopathic dilated cardiomyopathy are provided.Type: ApplicationFiled: February 11, 2020Publication date: August 13, 2020Inventors: Neil M. Cowen, Khaled Yamout
-
Publication number: 20200222417Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: ApplicationFiled: November 11, 2019Publication date: July 16, 2020Inventors: Neil M. COWEN, Khaled A. YAMOUT
-
Publication number: 20190117665Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: ApplicationFiled: August 23, 2018Publication date: April 25, 2019Inventors: Neil M. COWEN, Khaled A. YAMOUT
-
Patent number: 10085998Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: GrantFiled: June 28, 2016Date of Patent: October 2, 2018Assignee: Essentialis, Inc.Inventors: Neil M. Cowen, Khaled A. Yamout
-
Publication number: 20170143732Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: ApplicationFiled: June 28, 2016Publication date: May 25, 2017Applicant: Essentialis, Inc.Inventors: Neil M. Cowen, Khaled A. Yamout
-
Patent number: 9381202Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: GrantFiled: March 18, 2013Date of Patent: July 5, 2016Assignee: ESSENTIALIS, INC.Inventors: Neil M. Cowen, Khaled A. Yamout
-
Publication number: 20130225806Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: ApplicationFiled: March 18, 2013Publication date: August 29, 2013Applicant: Essentialis, Inc.Inventors: Neil M. Cowen, Khaled A. Yamout
-
Publication number: 20100256360Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: ApplicationFiled: June 18, 2010Publication date: October 7, 2010Inventors: Neil M. Cowen, Khaled A. Yamout
-
Patent number: 7799777Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: GrantFiled: December 20, 2006Date of Patent: September 21, 2010Assignee: Essentialis, Inc.Inventors: Neil M. Cowen, Khaled A. Yamout
-
Publication number: 20100028429Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: ApplicationFiled: July 31, 2009Publication date: February 4, 2010Inventors: Neil M. Cowen, Khaled A. Yamout
-
Patent number: 7572789Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: GrantFiled: February 24, 2009Date of Patent: August 11, 2009Assignee: Essentialis, Inc.Inventors: Neil M. Cowen, Kenneth B. Kashkin, Khaled A. Yamout
-
Publication number: 20090148526Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: ApplicationFiled: February 24, 2009Publication date: June 11, 2009Inventors: Neil M. Cowen, Kenneth B. Kashkin, Khaled A. Yamout
-
Publication number: 20070191351Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: ApplicationFiled: December 20, 2006Publication date: August 16, 2007Inventors: Neil Cowen, Kenneth Kashkin, Khaled Yamout
-
Patent number: 7037669Abstract: Methods, compositions and kits are disclosed. Enzyme conjugates of Formula I may be employed in assays for the determination of an amphetamine and/or a methamphetamine. Immunogenic conjugates of Formula I may be employed to prepare antibodies for an amphetamine and/or for a methamphetamine for use in assays for the determination of an amphetamine and/or a methamphetamine. The enzyme conjugates may also be employed to screen antibodies for use in such methods.Type: GrantFiled: March 22, 2004Date of Patent: May 2, 2006Assignee: Dade Behring Inc.Inventors: Yi Feng Zheng, Khaled A. Yamout, Donald E. Berger, Jr., Mae W. Hu, Hshiou-ting Liu
-
Publication number: 20050208603Abstract: Methods, compositions and kits are disclosed. Enzyme conjugates of Formula I may be employed in assays for the determination of an amphetamine and/or a methamphetamine. Immunogenic conjugates of Formula I may be employed to prepare antibodies for an amphetamine and/or for a methamphetamine for use in assays for the determination of an amphetamine and/or a methamphetamine. The enzyme conjugates may also be employed to screen antibodies for use in such methods.Type: ApplicationFiled: March 22, 2004Publication date: September 22, 2005Inventors: Yi Zheng, Khaled Yamout, Donald Berger, Mae Hu, Hshiou-Ting Liu